Coldplay may have answered EMI's rumored hopes
Elizabeth Taylor and Kathy Ireland walk away from jewelry company
More controls not the answer for China
KKR still has IPO envy?
Liquidnet looks for IPO liquidity
Energy Recovery: a cleantech deal hits the IPO market
Booze a defensive play in a bear market
Dollar rises vs euro after ECB's Trichet signals one rate hike may be enough
Who will make the next generation of thinner TVs: Samsung, Sony, Panasonic or Toshiba?_thumbnail.gif){kind=logo}
Analyst downgrades: NVDA, AFLYY and UNH
Sprint Nextel finally in the midst of a turnaround?
U.S. weekly jobless claims pass 400k, signaling further economic slowing
Blockbuster could come back for Circuit City?
Yahoo! (YHOO) looks for another partner
Before the bell: AMR, GOOG, AAPL
Lehman issuing stock to employees smells of desperation
.gif){kind=logo}
MOST NOTEWORTHY: AstraZeneca, Massey Energy and Freeport McMoRan were today's noteworthy upgrades:
- Dresdner Kleinwort upgraded shares of AstraZeneca (NYSE: AZN) to Buy from Hold following the company's settlement with Ranbaxy on the Nexium patent.
- Massey Energy (NYSE: MEE) was raised to Overweight from Neutral at Massey Energy citing the company's leverage to metallurgical coal prices in 2009.
- Freeport McMoRan (NYSE: FCX) was upgraded at HSBC to Overweight from Neutral on valuation.
OTHER UPGRADES:
- Arcelor Mittal (NYSE: MT) was upgraded to Buy from Hold at Citigroup.
- Merrill upgraded Bernis (NYSE: BMS) to Neutral from Sell.
